

AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME

Abstract

Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA- A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/Tyr D+ cells and as such can be used in diagnostics and therapy.

[No suitable figure]